{"id":36093,"date":"2025-10-27T10:21:05","date_gmt":"2025-10-27T09:21:05","guid":{"rendered":"https:\/\/ggba.swiss\/onward-medical-raises-over-eur-50-million-to-advance-spinal-cord-therapies\/"},"modified":"2025-10-27T10:22:46","modified_gmt":"2025-10-27T09:22:46","slug":"onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/","title":{"rendered":"ONWARD Medical l\u00e8ve plus de EUR 50 millions pour faire progresser ses th\u00e9rapies de la moelle \u00e9pini\u00e8re"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.onwd.com\/\">ONWARD Medical<\/a>, leader mondial des technologies de stimulation de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 50,85 millions gr\u00e2ce \u00e0 un placement priv\u00e9 de 11,3 millions de nouvelles actions au prix de EUR 4,50 chacune, soutenu par une forte demande d\u2019investisseurs institutionnels. L\u2019op\u00e9ration a \u00e9t\u00e9 men\u00e9e par Ottobock, avec la participation de l\u2019investisseur en sant\u00e9 Invus et du ASR Global Impact Equity Fund, aux c\u00f4t\u00e9s d\u2019autres partenaires de long terme.<\/p>\n\n\n\n<p>Bas\u00e9e aux Pays-Bas et dot\u00e9e d\u2019un centre scientifique et d\u2019ing\u00e9nierie \u00e0 Lausanne, ONWARD d\u00e9veloppe ARC Therapy, une gamme de syst\u00e8mes implantables et non invasifs qui d\u00e9livrent une stimulation \u00e9lectrique cibl\u00e9e \u00e0 la moelle \u00e9pini\u00e8re. Ces technologies visent \u00e0 restaurer le mouvement, la fonction et l\u2019ind\u00e9pendance des personnes vivant avec une l\u00e9sion de la moelle \u00e9pini\u00e8re (SCI) ou d\u2019autres handicaps moteurs.<\/p>\n\n\n\n<p>\u00c0 la suite de <a href=\"https:\/\/ggba.swiss\/fr\/onward-medical-recoit-une-autorisation-de-la-fda-pour-son-systeme-de-stimulation-de-la-moelle-epiniere\/\">l\u2019autorisation de la FDA obtenue d\u00e9but 2025 pour son syst\u00e8me ARC-EX<\/a>, ONWARD a franchi une \u00e9tape majeure en devenant une entreprise commerciale, pr\u00e9parant le d\u00e9ploiement du dispositif aux \u00c9tats-Unis et en Europe. Parall\u00e8lement, la soci\u00e9t\u00e9 fait progresser son syst\u00e8me implantable ARC-IM, con\u00e7u pour \u00eatre associ\u00e9 \u00e0 une interface cerveau-ordinateur (BCI) permettant d\u2019activer le mouvement par la pens\u00e9e.<\/p>\n\n\n\n<p>Selon Dave Marver, CEO d\u2019ONWARD Medical, cette lev\u00e9e de fonds soutient la mission de l\u2019entreprise visant \u00e0 \u00e9largir l\u2019acc\u00e8s \u00e0 ses th\u00e9rapies et \u00e0 acc\u00e9l\u00e9rer l\u2019innovation :<\/p>\n\n\n\n<p>\u00ab Nous pr\u00e9voyons d\u2019utiliser ce capital pour d\u00e9velopper les activit\u00e9s commerciales d\u2019ARC-EX tout en faisant progresser notre portefeuille avec le lancement pr\u00e9vu de notre \u00e9tude pivot pour le syst\u00e8me implantable ARC-IM. Cette op\u00e9ration alimente notre mission : proposer des th\u00e9rapies qui restaurent le mouvement, la fonction et l\u2019ind\u00e9pendance apr\u00e8s une l\u00e9sion de la moelle \u00e9pini\u00e8re. \u00bb<\/p>\n\n\n\n<p>Ce nouveau financement prolonge la solidit\u00e9 financi\u00e8re d\u2019ONWARD jusqu\u2019\u00e0 la fin de 2026, avec 40% des fonds d\u00e9di\u00e9s au d\u00e9veloppement d\u2019ARC-IM, 30% \u00e0 la commercialisation d\u2019ARC-EX, et le reste destin\u00e9 \u00e0 la croissance op\u00e9rationnelle et aux besoins g\u00e9n\u00e9raux de l\u2019entreprise.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019entreprise de neurotechnologie prolonge son horizon financier jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.<\/p>\n","protected":false},"author":6,"featured_media":36090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1188,1181,1163,1239,1141,1142],"class_list":["post-36093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-healthcare-fr-2","tag-medical-devices-fr","tag-medtech-fr-2","tag-neuroscience-fr-2","tag-personalized-medicine-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ONWARD Medical l\u00e8ve plus de EUR 50 millions | GGBa<\/title>\n<meta name=\"description\" content=\"ONWARD Medical prolonge sa solidit\u00e9 financi\u00e8re jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ONWARD Medical l\u00e8ve plus de EUR 50 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"ONWARD Medical prolonge sa solidit\u00e9 financi\u00e8re jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T09:21:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T09:22:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"ONWARD Medical l\u00e8ve plus de EUR 50 millions pour faire progresser ses th\u00e9rapies de la moelle \u00e9pini\u00e8re\",\"datePublished\":\"2025-10-27T09:21:05+00:00\",\"dateModified\":\"2025-10-27T09:22:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\"},\"wordCount\":380,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Medical Devices\",\"Medtech\",\"Neuroscience\",\"Personalized Medicine\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\",\"name\":\"ONWARD Medical l\u00e8ve plus de EUR 50 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg\",\"datePublished\":\"2025-10-27T09:21:05+00:00\",\"dateModified\":\"2025-10-27T09:22:46+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ONWARD Medical prolonge sa solidit\u00e9 financi\u00e8re jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Le syst\u00e8me ARC-EX d\u2019ONWARD Medical d\u00e9livre une stimulation non invasive de la moelle \u00e9pini\u00e8re pour restaurer le mouvement et la sensation apr\u00e8s une l\u00e9sion. | \u00a9 ONWARD Medical\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ONWARD Medical l\u00e8ve plus de EUR 50 millions pour faire progresser ses th\u00e9rapies de la moelle \u00e9pini\u00e8re\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ONWARD Medical l\u00e8ve plus de EUR 50 millions | GGBa","description":"ONWARD Medical prolonge sa solidit\u00e9 financi\u00e8re jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/","og_locale":"fr_FR","og_type":"article","og_title":"ONWARD Medical l\u00e8ve plus de EUR 50 millions | GGBa","og_description":"ONWARD Medical prolonge sa solidit\u00e9 financi\u00e8re jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.","og_url":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-27T09:21:05+00:00","article_modified_time":"2025-10-27T09:22:46+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"ONWARD Medical l\u00e8ve plus de EUR 50 millions pour faire progresser ses th\u00e9rapies de la moelle \u00e9pini\u00e8re","datePublished":"2025-10-27T09:21:05+00:00","dateModified":"2025-10-27T09:22:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/"},"wordCount":380,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg","keywords":["Financing","Healthcare","Medical Devices","Medtech","Neuroscience","Personalized Medicine","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/","url":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/","name":"ONWARD Medical l\u00e8ve plus de EUR 50 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg","datePublished":"2025-10-27T09:21:05+00:00","dateModified":"2025-10-27T09:22:46+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ONWARD Medical prolonge sa solidit\u00e9 financi\u00e8re jusqu\u2019en 2026 et pr\u00e9pare l\u2019expansion commerciale et clinique de ses syst\u00e8mes ARC Therapy.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Onward-Medical-Arc-Ex-and-Pouch-1180x811-1.jpg","width":1180,"height":811,"caption":"Le syst\u00e8me ARC-EX d\u2019ONWARD Medical d\u00e9livre une stimulation non invasive de la moelle \u00e9pini\u00e8re pour restaurer le mouvement et la sensation apr\u00e8s une l\u00e9sion. | \u00a9 ONWARD Medical"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"ONWARD Medical l\u00e8ve plus de EUR 50 millions pour faire progresser ses th\u00e9rapies de la moelle \u00e9pini\u00e8re"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=36093"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36093\/revisions"}],"predecessor-version":[{"id":36095,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36093\/revisions\/36095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/36090"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=36093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=36093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=36093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}